Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 43

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Obesity+1

Not yet recruiting

Tirzepatide versus CPAP and Lifestyle Modification for Obstructive Sleep Apnea in Adults ≥ 65 years with Overweight or Obesity – Randomized Trial

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Tirzepatide
  • Sponsor:Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Non-small cell lung cancer

Not yet recruiting

Safety and efficacy of rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Bronchiectasis

Not yet recruiting

A Study of SAR445399 in Adults Aged 18‑80 with Non‑cystic Fibrosis Bronchiectasis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Non-small cell lung cancer

Not yet recruiting

Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Bronchiectasis

Not yet recruiting

Efficacy of colistimethate sodium and ciprofloxacin for eradicating primary Pseudomonas aeruginosa infection in adults with bronchiectasis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Granulomatosis with polyangiitis+1

Not yet recruiting

Rituximab versus clinic‑biological monitoring for ANCA reactivation in patients with GPA or MPA (with prednisolone)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Asthma

Not yet recruiting

Evaluating Gradual Interval Extension of Tezepelumab in Drug Combination for Patients with Severe Asthma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Amsterdam UMC Stichting

Pulmonary embolism

Not yet recruiting

Enoxaparin or drug combination versus no anticoagulant treatment for incidental subsegmental pulmonary embolism in cancer patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Region Hovedstaden

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

Neoplasm malignant+1

Not yet recruiting

Phase I/II study of DJI136 with drug combination in adult patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.